New entities in pathological classification and new therapeutic options in renal cell carcinoma;Nouveautés anatomopathologiques et évolution des thérapeutiques actuelles dans les cancers du rein

Bulletin du Cancer

Volumn 93, Issue 1, 2006, Pages 91-100

  Bay, Jacques Olivier ^a   Penault Llorca, Frédérique ^a   Ravaud, Alain ^b   Chevreau, Christine ^c   Négrier, Sylvie ^d   Escudier, Bernard ^e  

^a CENTRE JEAN PERRIN   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antiangiogenic drugs; Immunotherapy; Renal cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

AG 013736; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; INTERLEUKIN 2; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HLA MATCHING; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; NONMYELOABLATIVE CONDITIONING; PREDICTION; PROGNOSIS; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PROGNOSIS; PROTEIN-TYROSINE KINASES; STEM CELL TRANSPLANTATION; SURVIVAL; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33144462392     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Penault-Llorca F, Bay JO. Asco 2005: la biologie a parlé. Bull Cancer 2005; 92: 623-4.
2. Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, et al. Recommandations pour la prise en charge des tumeurs stromales gastrointestinales (GIST). Bull Cancer 2005; 92: 907-18.
3. Guilhot F. L'anti-tyrosine kinase: le début du traitement moléculaire des cancers et les premiers résultats. Bull Cancer 2001; 88: 659-60.
4. Andre T, Louvet C, de Gramont A. Cancer du côlon: quoi de neuf en 2004. Bull Cancer 2004; 91: 75-80.
5. Fayette J, Le Chevalier T, Soria JC. Implications thérapeutiques du récepteur du facteur de croissance épidermique dans le cancer bronchique. Bull Cancer 2003; 90: S233-S240.
6. Peffault de Latour R, Marie Robin M, Bay JO. Place des anticorps monoclonaux dans la prise en charge des lymphomes et des leucémies en 2005. Bull Cancer 2006; 93: 107-18.
7. Bay JO, Dhedin N, Goerner M, Vannier JP, Marie-Cardine A, Stamatoullas A, et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005; 80: 782-8.
8. Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? BioDrugs 2005; 19: 211-31.
9. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. In: WHO international classification of tumors, pathology and genetics. Tumors of the urinary system and male genital organs. Lyon: IARC Press, 2004: 9-88.
10. Comperat EV, Vasiliu V, Ferlicot S, Camparo P, Sibony M, Vieillefond A. Les cancers du rein: nouvelle classification. Ann Pathol 2005; 25: 117-33.
11. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90.
12. Neumann HP, Bender BU. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med 1998; 243: 541-5.
13. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5.
14. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004; 10: 5464-71.
15. Kovacs G. Molecular differential pathology of renal cell tumours. Histopathology 1993; 22: 1-8.
16. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 1991; 3: 249-55.
17. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001; 61: 7277-81.
18. Furge KA, Lucas KA, Takahashi M, Sugimura J, Kort EJ, Kanayama HO, et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004; 64: 4117-21.
19. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002; 13: 1460-8.
20. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40.
21. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003; 170: 1141-5.
22. Elson PJ, Manola JB, Mazumdar M, Bacik JM, Supers SJ. for the international kidney cancer working group. Prognostic factors for survival in patients with metastatic renal cell carcinoma: a study from the Kidney Cancer Association's International Kidney Cancer Working Group (IKCWG). J Clin Oncol 2005; 23: 386s.
23. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363: 594-9.
24. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005; 7: 109-15.
25. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-9.
26. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-70.
27. Demerci D, Tatlisen A, Ekmekcioglu O, Ozcan N, Kaya R. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report. Urol Int 2004; 73: 54-8.
28. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Sust Rev 2005; 1: (CD001425).
29. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe français d'immunothérapie. N Engl J Med 1998; 338: 1272-8.
30. Négrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized Percy Quattro trial. J Clin Oncol 2005; 23: 380s.
31. Ravaud A. Thérapie cellulaire et cancer du rein. Bull Cancer 2003; 90: 711-21.
32. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-22.
33. Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, et al. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995; 41: 111-21.
34. Lesimple T, Moisan A, Guille F, Leberre C, Audran R, et al. Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J Immunother 2000; 23: 675-9.
35. Reid CD, Stackpoole A, Meager A, Tikerpae J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992; 149: 2681-8.
36. Marten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002; 51: 637-44.
37. Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 2003; 16: 175-82.
38. Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005; 54: 663-70.
39. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2003; 9: 1093.
40. Neves AR, Ensina LF, Anselmo LB, Leite KR, Buzaid AC, Camara-Lopes LH, et al. Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother 2005; 54: 61-6.
41. Bay JO, Choufi B, Tournilhac O, Faucher C, Blaise D. Transplantation de cellules hématopoïétique dans les tumeurs solides. Bull Cancer 2001; 88: 900-7.
42. Faucher C. Miniallogrefies de moelle osseuse (hématologie et tumeurs solides). Bull Cancer 2001; 88: 110-3.
43. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 34: 750-8.
44. Mena O, Igarashi T, Srinivasan R, Carvallo C, Takahashi Y, Re F, et al. Immunologic machanisms involved in the graft-vs-tumor (GVT) effect in renal cell carcinoma (RCC) following nonmyeloablative allogeneic peripheral blood stem cell transplantation. Blood 2001; 98: 856a.
45. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017-24.
46. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-6.
47. Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409-15.
48. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-61.
49. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-36.
50. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-41.
51. Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp Hematol 2004; 32: 599-606.
52. Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004; 10: 7799-811.
53. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant 2005; 35: 253-60.
54. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002; 13: 1029-35.
55. Escudier B, Venner P, Stern L, Donovan M, Croteau D, Champagne P, et al. Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy; lessons from a large phase III trial. J Clin Oncol 2004; 23: 393s.
56. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-18.
57. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
58. Spigel DR, Hainsworth JD, Sosman JA, Raefsky EL, Meluch AA, Edwards D, et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a phase II multicenter trial. J Clin Oncol 2005; 23: 387s.
59. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; (sous presse).
60. Hainsworth JD, Sosman JA, Spigel DR, Patton JF, Thompson DS, Sutton V, et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma (RCC): a Minnie Pearl Cancer Research Network phase I/II trial. J Clin Oncol 2005; 23: 388s.
61. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial. J Clin Oncol 2004; 22: 382s.
62. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 2005; 23: 380s.
63. Ratain M, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. J Clin Oncol 2004; 22: 382s; (abstract 4501).
64. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23: 380s.
65. Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refraxctory, metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23: 380s.
66. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, et al. Phase II trial of bonezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22: 3720-5.